Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia [0.03%]
费城染色体阳性成人急性淋巴细胞白血病再诱导治疗结果
Wei-Ying Jen,Elias Jabbour,Eitan Kugler et al.
Wei-Ying Jen et al.
Background: The historical results in adults with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) in second relapse treated with third-line therapy (Salvage 2) are extremely poor. Using standard c...
Potential Benefits and Harms of Screening Strategies for Monoclonal Gammopathy of Undetermined Significance in the US: A Simulation Study [0.03%]
美国筛查未定意义单克隆免疫球蛋白血症(MGUS)策略的潜在利弊：一项模拟研究
Ishfaq Ahmad,Rong Wang,Natalia Neparidze et al.
Ishfaq Ahmad et al.
Background: Multiple myeloma (MM) is preceded by monoclonal gammopathy of undetermined significance (MGUS), an asymptomatic premalignant condition. There are no recommendations for MGUS screening due to a lack of evidence...
Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model [0.03%]
美国多发性骨髓瘤四线后的治疗顺序对长期生存率的影响：基于仿真模型的CAR-T和双特异性抗体疗法组合的研究
Jodi Lipof,Brian Bloudek,Avik Ray et al.
Jodi Lipof et al.
Background: CAR T-cell therapies and bispecific antibodies (BsAb) are increasingly used in 4L+ relapsed/refractory multiple myeloma (RRMM), but long-term data to inform optimal sequencing are limited. ...
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [0.03%]
copanlisib联合venetoclax治疗复发/难治弥漫大B细胞淋巴瘤I期临床研究
Jennifer L Crombie,Austin I Kim,Robert Redd et al.
Jennifer L Crombie et al.
Background: Preclinical data support the combination of venetoclax and copanlisib in specific genomic subgroups of diffuse large B-cell lymphoma (DLBCL). ...
Autoimmune Features in Myelodysplastic Syndromes: Clinical and Molecular Heterogeneity With Integrated IPSS-M Analysis [0.03%]
骨髓增生异常综合征中的自身免疫特征：结合IPSS-M分析的临床和分子异质性研究
Yoonseo Jeong
Yoonseo Jeong
Background: Autoimmune features are increasingly recognized in myelodysplastic syndromes (MDS), but their clinical and molecular significance remains unclear. We aimed to characterize the clinicopathologic, cytogenetic, m...
SOHO State of the Art Updates and Next Questions | Progress in Clonal Hematopoiesis of Indeterminate Potential/Clonal Cytopenia of Uncertain Significance [0.03%]
SOHO最新研究进展和下一步问题|不确定潜能克隆性造血/意义未明克隆性血细胞减少症的进展
Jayanshu Jain,Uma Borate
Jayanshu Jain
Clonal hematopoiesis (CH) refers to the acquisition of somatic mutations in hematopoietic cells, which confers a risk of progression to myeloid malignancy, cardiovascular disease, and increased mortality. More widespread availability of nex...
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma [0.03%]
伊沙佐米、环磷酰胺和地塞米松( ICd )，联合或不联合达雷木单抗治疗复发多发性骨髓瘤患者的疗效研究
Shaji Kumar,Betsy Knopf,Erik Asmus et al.
Shaji Kumar et al.
Background: Proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies form the backbone of initial treatment for myeloma and play an important role in the treatment of relapsed disease. However, global acce...
Risk of Thromboembolic Events in Patients With Polycythemia Vera: A Real-World Observational Study [0.03%]
真实世界观察研究中的真性红细胞增多症患者的血栓事件风险
Andrew T Kuykendall,Arturo Molina,Nancy Reaven et al.
Andrew T Kuykendall et al.
Background: Polycythemia vera (PV) is a myeloproliferative neoplasm associated with an increased risk of thromboembolic and cardiovascular events. Patient...
Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function [0.03%]
贝伦塔马班单药治疗复发/难治多发性骨髓瘤且肾功能正常和不同程度受损患者的药代动力学和安全性
Xi Chen,Shawn Hakim,Yi Ting Kayla Lien et al.
Xi Chen et al.
Background: Assessment of drug pharmacokinetics in patients with multiple myeloma (MM) and renal impairment (RI) is important due to the potential for altered drug exposure. The phase 1 DREAMM-12 (NCT04398745) study evalu...
Prospective Study of Cytomegalovirus Reactivation in Patients With Multiple Myeloma Receiving Anti-CD38 and BCMA Therapies [0.03%]
靶向CD38和BCMA的治疗导致多发性骨髓瘤患者巨细胞病毒再激活：一项前瞻性研究
Emily Baneman,Samantha E Jacobs,Meenakshi Rana et al.
Emily Baneman et al.
Background: Cytomegalovirus (CMV) is an opportunistic pathogen that causes infection in certain immunocompromised hosts, but the risk of clinically significant CMV infection in patients with multiple myeloma (MM) is not w...